We are live on ! Find out more
MCM

M28 Capital Management Portfolio holdings

AUM $53.8M
1-Year Est. Return 28.63%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
+28.63%
3 Year Est. Return
+218.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$75.7M
AUM Growth
-$12.8M
Cap. Flow
-$13.8M
Cap. Flow %
-18.3%
Top 10 Hldgs %
97.31%
Holding
14
New
–
Increased
3
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
SLN
Silence Therapeutics
SLN
+$1.31M
2
CRIS icon
Curis
CRIS
+$1.23M
3
WVE icon
Wave Life Sciences
WVE
+$404K

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$5.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$4.51M
3
BBIO icon
BridgeBio Pharma
BBIO
+$2.08M
4
STOK icon
Stoke Therapeutics
STOK
+$1.99M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$1.85M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$25.7M 33.91%
7,050,000
+100,000
+1% +$404K
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$348M
$12.5M 16.55%
630,380
-91,700
-13% -$1.85M
IVVD icon
3
Invivyd
IVVD
$180M
$9.71M 12.83%
9,248,250
– –
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$5.18M 6.85%
197,700
– –
CRIS icon
5
Curis
CRIS
$9.53M
$4.98M 6.58%
15,000
+3,795
+34% +$1.23M
STOK icon
6
Stoke Therapeutics
STOK
$1.82B
$3.68M 4.86%
346,190
-186,700
-35% -$1.99M
TGTX icon
7
TG Therapeutics
TGTX
$8.58B
$3.54M 4.68%
142,500
-197,000
-58% -$5.09M
PRQR icon
8
ProQR Therapeutics
PRQR
$243M
$3.1M 4.09%
1,910,600
– –
BBIO icon
9
BridgeBio Pharma
BBIO
$16.5B
$2.86M 3.78%
166,200
-138,500
-45% -$2.08M
ARWR icon
10
Arrowhead Research
ARWR
$12.1B
$2.4M 3.18%
67,400
– –
SLN
11
Silence Therapeutics
SLN
$521M
$2M 2.64%
363,800
+217,900
+149% +$1.31M
NEXI
12
DELISTED
NexImmune, Inc. Common Stock
NEXI
$37.6K 0.05%
5,338
– –
ATRA icon
13
Atara Biotherapeutics
ATRA
$71.2M
– –
-17,572
Closed -$1.27M
IONS icon
14
Ionis Pharmaceuticals
IONS
$9.35B
– –
-126,300
Closed -$4.51M

Similar funds

NCM
Notable Capital Management Menlo Park, California $53.4M AUM 10.98% 1-Year Est. Return
WEO
William E. Oberndorf $53.3M AUM 10.89% 1-Year Est. Return
MML
Mercato Management Legacy Cottonwood Heights, Utah $54.3M AUM
CAM
Copperwood Asset Management Houston, Texas $54.4M AUM
ETCM
Evolutionary Tree Capital Management Alexandria, Virginia $53.2M AUM 13.56% 1-Year Est. Return
AA
Ascent Advisors Mankato, Minnesota $54.4M AUM
TP
Toronado Partners San Francisco, California $53M AUM 13.38% 1-Year Est. Return
GMEI
Global Media & Entertainment Investments Nassau, Bahamas $53M AUM 0% 1-Year Est. Return

M28 Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, M28 Capital Management held 14 positions worth $75.7M, down 14% from $88.4M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

M28 Capital Management withdrew a net $13.8M in Q2 2023, closing 2 positions and reducing 4 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $4.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, M28 Capital Management added an estimated $1.31M to Silence Therapeutics.

  • M28 Capital Management added most to Silence Therapeutics in Q2 2023, an estimated $1.31M increase.
  • M28 Capital Management's biggest Q2 2023 reduction was TG Therapeutics, cutting an estimated $5.09M.
  • M28 Capital Management fully exited Ionis Pharmaceuticals in Q2 2023, selling an estimated $4.51M.
  • M28 Capital Management's ten largest holdings make up 97% of its $75.7M portfolio in Q2 2023.
  • M28 Capital Management opened 0 new positions and closed 2 in Q2 2023.
  • M28 Capital Management's portfolio value fell 14% quarter-over-quarter to $75.7M.

Based on M28 Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.